linjc16/ctgov huggingface dataset:
RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and identify biomarkers related to cancer. PURPOSE: This research study is studying RNA biomarkers in tissue samples from infants with acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: Sequence the microRNAs present in 20 infant AML samples as a pilot study. Compare microRNAs present in infant AML samples to infant ALL samples that are being concurrently sequenced in a separate study to identify lineage- and translocation-specific microRNAs. OUTLINE: This is a multicenter study. Previously collected cryopreserved cells from diagnosis are sequenced using reverse transcriptase-PCR.

Official Title
-----------------
SCOR in Targeted Therapies for Infant Leukemias Project 4: MicroRNA Sequencing of Infant AML

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: RNA analysis
* Genetic: nucleic acid sequencing
* Genetic: reverse transcriptase-polymerase chain reaction
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia Available cryopreserved cells from diagnosis PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: RNA analysis|nan|
|Genetic: nucleic acid sequencing|nan|
|Genetic: reverse transcriptase-polymerase chain reaction|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sequence of the microRNAs present in 20 infant acute myeloid leukemia (AML) samples |  |  | 
| Comparison of microRNAs present in infant AML samples to infant acute lymphoblastic leukemia samples to identify lineage- and translocation-specific microRNAs |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood acute myeloid leukemia/other myeloid malignancies
S-pantoprazole 10mg Phase III Clinical Study

Study Overview
=================
Brief Summary
-----------------
This clinical study hypothesized that S-pantoprazole 10mg would be effective to treat Non erosive Reflux Disease than placebo.

Conditions
-----------------
Non Erosive Reflux Disease

Intervention / Treatment
-----------------
* Drug: S-pantoprazole 10mg
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults between the ages of 19 and 75 inclusive Patient with a history of heartburn or acid regurgitation for at least 3 months. Those with episodes of heartburn for 2 days or more during the last 7 days prior to baseline Patients negative for erosive esophagitis confirmed by esophagogastroduodenoscopy(EGD) performed within 7 days of screening Capable of providing written informed consent, willing and able to a comply with all procedures of the study Exclusion Criteria: History of endoscopic erosive esophagitis(EE) at screening EGD. Historical evidence of the following disease/conditions : symptom of Irritable bowel syndrome More tha 3cm endoscopic Barrett's esophagus or significant dysplastic changes in the esophagus Proton Pump Inhibitor(PPI) within 4 weeks prior to the baseline visit H2-receptor antagonist, sucralfate, prokinetics, Non Steroidal Antiinflammatory Drugs(NSAIDs) (except low dose aspirin) during the 2 weeks prior to the screening Historical evidence of the following disease/conditions during 3 months: Zollinger-Ellison syndrome, the primary esophageal motility disorders achalasia, esophageal stricture, pancreatitis, gastric ulcer, evidence of upper G.I. malignancy, pancreatitis, malabsorption, severe cardiovascular or pulmonary disease, severe liver disease, severe renal disease, cerebral vascular disease, Known hypersensitivity to any component of drug pregnancy or lactation (F only)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: S-pantoprazole 10mg<br>S-pantoprazole 10mg Tablet once daily for 4 weeks | Drug: S-pantoprazole 10mg<br> <br> |
| Placebo Comparator: Placebo<br>Placebo tablet for the test drug | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the efficacy , as defined by complete resolution of heartburn (HB) per Questionnaire, of 4 weeks of treatment of S-pantoprazole 10mg qd compared to Placebo in subjects with symptomatic gastro-esophageal reflux disease |  | 4 weeks |
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

Study Overview
=================
Brief Summary
-----------------
Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the likelihood of complications and death. The high blood pressure explains some but not all of this increase in heart size. This study will investigate the other causes, and will measure the heart muscle 'thickness' very accurately using the latest and most accurate technique called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening remains to be determined. We hope to be able to show that by specifically targeting the cause of heart muscle thickening we can reduce its occurrence more effectively than by other standard means of blood pressure treatment

Official Title
-----------------
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

Conditions
-----------------
Hypertension, Left Ventricular Hypertrophy

Intervention / Treatment
-----------------
* Drug: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD
* Drug: Valsartan 160mg OD; Moxonidine 400mcg OD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recently diagnosed essential hypertension (within 6 months). Age 25 to 80 years; Weight < 100kg. Sinus rhythm without significant ventricular or atrial ectopy. Exclusion Criteria: Current angiotensin II receptor antagonist or ACE Inhibitor treatment. Contra-indication to any of the protocol anti-hypertensive agents. Angina requiring treatment with a Beta blocker or calcium antagonist Any disease affecting the autonomic nervous system e.g. congestive cardiac failure, diabetes, neurological disease, malignancy, pregnancy. Contraindication to MRI (pacemaker, intra-orbital debris, intra-auricular implants, intra-cranial clips, history of claustrophobia, inability to lie supine for 15 minutes etc).

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Neurohormonal stimulatory arm | Drug: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD<br> <br> |
| Experimental: 2<br>Neurohormonal inhibitory arm | Drug: Valsartan 160mg OD; Moxonidine 400mcg OD<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome measure is decrease in LV mass as assessed by cardiac MRI compared between the two treatment groups. |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Left Ventricular Hypertrophy
Endoscopic Grading of Intestinal Metaplasia

Study Overview
=================
Brief Summary
-----------------
Long-term Helicobacter pylori infection causes premalignant gastric conditions, such as atrophic gastritis and intestinal metaplasia. Image-enhanced endoscopy techniques such as narrow-band imaging (NBI) and magnifying endoscopy improve the diagnosis of gastric intestinal metaplasia (GIM). However, there are no comparative data on the utility of NBI and magnifying endoscopy for diagnosing GIM.

Detailed Description
-----------------
This study aims to evaluate the diagnostic performance of NBI and magnifying endoscopy for GIM in a country with high risk of gastric premalignant lesions.

Official Title
-----------------
Endoscopic Grading of Gastric Intestinal Metaplasia: a Validation Study in Korea

Conditions
-----------------
Narrow-band Imaging, Magnifying Endoscopy, Gastric Intestinal Metaplasia

Intervention / Treatment
-----------------
* Procedure: Narrow-band imaging endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gastroscopy can be performed Pathological analysis can be performed for analysis of gastric atrophy and intestinal metaplasia Exclusion Criteria: Age < 20 or > 80 years Anemia (serum hemoglobin level < 10 g/dL) Severe systemic disease Advanced chronic liver disease Use of certain medications, including proton pump inhibitors, H2-receptor antagonists, or antibiotics History of H. pylori eradication History of gastric surgery Recent history of upper gastrointestinal bleeding

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gastric intestinal metaplasia | Gastric intestinal metaplasia would be assessed using pathological examination. | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Degree of chronic gastritis | Gastric atrophy would be evaluated on the basis of histopathological examination (updated Sydney system). | 4 weeks |
Magnetic Nanoparticle Sperm Separation for Teratozoospermia Male and Women Older Than 35 Years

Study Overview
=================
Brief Summary
-----------------
Women over 35 years old are likely to suffer from impaired oocyte repair capacity. Teratozoospermia is a condition reflects morphological affection of sperm. These spermatozoa would add an extra burden on the oocyte after ICSI. Whether selecting mature sperm by magnetic nanoparticle protocol would provide a more competent sperm to a likely affected oocyte would improve ICSI outcomes is the question of this research.

Official Title
-----------------
Magnetic Nanoparticle Sperm Separation for ICSI Cycles With Teratozoospermia and Over 35 Years Old Women Age

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Other: Sperm preparation for ICSI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women indicated for ICSI but with teratozoospermia Exclusion Criteria: Women not failing in this group

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Magnetic nanoparticle selection for teratozoospermia<br> | Other: Sperm preparation for ICSI<br>* A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women<br>|
| No Intervention: Density gradient centrifugation for teratozoospermia<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing pregnancy rate |  | Twelve weeks of gestation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Embryo development after ICSI |  | Six days of culture |
Preliminary Data for Breath Biofeedback of Dietary Compliance

Study Overview
=================
Brief Summary
-----------------
The investigators ultimate goal is to test the hypothesis that immediate feedback of dietary adherence will enhance compliance to a weight loss program. This study deals directly with gathering the needed preliminary data for a grant submission.

Official Title
-----------------
Preliminary Data for Breath Biofeedback of Dietary Compliance

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: Dietary Adherence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males or females age 18 or older Exclusion Criteria: Chronic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breath CO2, ketones, aldehydes, alcohols |  | Daily for 5-7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity
Implant Placement in Horizontally Deficient Maxillary Aesthetic Zone With Simultaneous Soft Tissue Augmentation

Study Overview
=================
Brief Summary
-----------------
Tooth extraction in maxillary esthetic zone is accomplished with great dimensional changes of the alveolar ridge, different procedures have been tested to compensate these dimensional alteration, such as Hard bone augmentation, Soft tissue augmentation Or augmentation of both together. Hence, the present study aimed to evaluate pink esthetic score, clinical implant stability and bucco-palatal dimensional changes in the maxillary esthetic zone treated by implant placement with simultaneous soft tissue augmentation using de-epithelialized free gingival graft.

Official Title
-----------------
Implant Placement in Horizontally Deficient Maxillary Aesthetic Zone With Simultaneous Soft Tissue Augmentation Using De-epithelialized Free Gingival Graft and Its Effect on Esthetics. a Case Series Study

Conditions
-----------------
Implant or Graft; Rejection

Intervention / Treatment
-----------------
* Procedure: implant placement with simultaneous soft tissue augmentation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient of both sexes with missing teeth in the maxillary aesthetic zone. Exclusion Criteria: Patients with systemic disease that may affect bone quality or bone healing.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: patients with missing teeth in maxillary aesthetic zone<br> | Procedure: implant placement with simultaneous soft tissue augmentation<br>* implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pink esthetic score | pink esthetic score evaluated pre-operative and 6 month post-operative (PES scale 0-1-2 , ''2'' the best , ''0'' the worst | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant stability quotient |  | 6 month |
Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate 450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg extended release tablet under fasting conditions using a single-dose, randomized, three-treatment, three-period, six-sequence crossover design.

Official Title
-----------------
A Single Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Bioequivalency Study of 450 mg Lithium Carbonate Extended Release Tablets Under Fasting Conditions

Conditions
-----------------
Bipolar Disorder

Intervention / Treatment
-----------------
* Drug: Lithium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: Participation in a clinicl trial within 30 days prior to study initiation. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lithium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence |  | Baseline, Three period, Fourteen day washout |
Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke

Study Overview
=================
Brief Summary
-----------------
Incidence of strokes has increased these last 20 years in young population. This rise could be linked to alcohol, tobacco or drug use like cannabis. Cannabis has previously been descripted as a potential factor of reversible vasoconstriction. The main objective is to show that an exhaustive assessment of a stroke facing a young person frequently lead to a diagnostic of reversible vasoconstriction due to cannabis use. Evaluation will focus on prevalence of strokes secondary to a reversible vasoconstriction attributable to cannabis in young subjects. There's a real public healthcare interest in terms of primary and secondary prevention to evaluate the role of cannabis as a risk factor of stroke in young population.

Official Title
-----------------
Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke

Conditions
-----------------
Stroke, Cannabis Use

Intervention / Treatment
-----------------
* Other: Drug urinal test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject between 18 and 45 years old Stroke confirmed by medical imaging Written informed consent (subject, nearby or emergency procedure) Subject affiliate to a local healthcare insurance office For female of childbearing potential, an adequate contraceptive measur Exclusion Criteria: Subject with psychiatric disorder, unable to understand the study or cooperate Subject under guardianship or forfeiture of liberty Pregnant or breastfeeding woman Subject in period of exclusion due to another study or still in follow-up of an interventional study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: Cannabis User
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Cannabis User<br> | Other: Drug urinal test<br>* Non Applicable<br>* Other names: Transcranial Doppler Ultrasound;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation Cannabis use |  | 12 months | 
| Reversible vasoconstriction on medical imaging of intracranial arteries at different moment | medical imaging of intracranial arteries will show new stenoses (topography, number, evolution), and new ischemic or cerebral haemorrhagic lesions | 12 months. |